We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Magnus Ofstad. In this article, we will summarize the ...

In January, Sanofi agreed a $1.45 billion deal to acquire UK biotech Kymab and its lead drug KY1005, an OX40 antibody that like KHK4083 has already cleared a phase 2 trial in atopic dermatitis.

Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five ...

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase ...

The firm's decision follows Astria's announcement of the initiation of a Phase 1a study for STAR-0310, a monoclonal antibody and OX40 antagonist, aimed at treating atopic dermatitis and ...

The three pipelines-in-a-product are anti-OX40 antibody amlitelimab, which recently generated positive phase 2b results in atopic dermatitis, anti-CD40L antibody frexalimab which is in mid-stage ...

This expansion was greater than that seen with an anti-OX40 agonist antibody. When the two antibodies were given together, they stimulated greater expansion of CD8+ T cells than either alone ...

Ichnos is also exploring partnerships for ISB 830 (telazorlimab), a tumor necrosis factor receptor superfamily member 4 (OX40) antagonist monoclonal antibody that successfully completed a phase 2b ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 ...

About amlitelimabAmlitelimab is a fully human non-T cell depleting monoclonal antibody that blocks OX40-Ligand, a key immune regulator, and has the potential to be a first- or best-in-class ...

Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website ...